4530 Stock Overview
Manufactures and sells pharmaceuticals in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Hisamitsu Pharmaceutical Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥4,119.00 |
| 52 Week High | JP¥4,593.00 |
| 52 Week Low | JP¥3,600.00 |
| Beta | 0.33 |
| 1 Month Change | -3.85% |
| 3 Month Change | 4.86% |
| 1 Year Change | -4.12% |
| 3 Year Change | 1.83% |
| 5 Year Change | -24.00% |
| Change since IPO | 834.01% |
Recent News & Updates
Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00
Nov 27
Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00
Nov 08We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt
Nov 04Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations
Oct 17Recent updates
Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00
Nov 27Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00
Nov 08We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt
Nov 04Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations
Oct 17Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing
Sep 16Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 20Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00
Jul 26Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year
Jul 11Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00
Jun 27Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00
Jun 13Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price
Apr 09Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching
Mar 18Shareholder Returns
| 4530 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -3.4% | -0.1% | -1.5% |
| 1Y | -4.1% | 10.6% | 13.7% |
Return vs Industry: 4530 underperformed the JP Pharmaceuticals industry which returned 10.6% over the past year.
Return vs Market: 4530 underperformed the JP Market which returned 13.7% over the past year.
Price Volatility
| 4530 volatility | |
|---|---|
| 4530 Average Weekly Movement | 2.5% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4530 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4530's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1847 | 2,759 | Kazue Nakatomi | www.global.hisamitsu |
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders.
Hisamitsu Pharmaceutical Co., Inc. Fundamentals Summary
| 4530 fundamental statistics | |
|---|---|
| Market cap | JP¥302.10b |
| Earnings (TTM) | JP¥14.65b |
| Revenue (TTM) | JP¥150.19b |
20.6x
P/E Ratio2.0x
P/S RatioIs 4530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4530 income statement (TTM) | |
|---|---|
| Revenue | JP¥150.19b |
| Cost of Revenue | JP¥65.45b |
| Gross Profit | JP¥84.73b |
| Other Expenses | JP¥70.08b |
| Earnings | JP¥14.65b |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
Jan 09, 2025
| Earnings per share (EPS) | 199.75 |
| Gross Margin | 56.42% |
| Net Profit Margin | 9.75% |
| Debt/Equity Ratio | 0.4% |
How did 4530 perform over the long term?
See historical performance and comparisonDividends
2.1%
Current Dividend Yield66%
Payout RatioDoes 4530 pay a reliable dividends?
See 4530 dividend history and benchmarks| Hisamitsu Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Feb 27 2025 |
| Dividend Pay Date | May 26 2025 |
| Days until Ex dividend | 67 days |
| Days until Dividend pay date | 155 days |
Does 4530 pay a reliable dividends?
See 4530 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 21:52 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/02/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hisamitsu Pharmaceutical Co., Inc. is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Toshiro Yoshinaga | Aizawa Securities Co. Ltd. |
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |